Compare TCRX & OM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCRX | OM |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 59.2M |
| IPO Year | 2021 | 2020 |
| Metric | TCRX | OM |
|---|---|---|
| Price | $0.24 | $4.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $1.00 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 761.4K | 185.8K |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,325,000.00 | ★ $119,476,000.00 |
| Revenue This Year | N/A | $5.43 |
| Revenue Next Year | N/A | $10.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 266.65 | 5.09 |
| 52 Week Low | $0.22 | $2.84 |
| 52 Week High | $2.57 | $15.94 |
| Indicator | TCRX | OM |
|---|---|---|
| Relative Strength Index (RSI) | 24.14 | 62.99 |
| Support Level | N/A | $3.00 |
| Resistance Level | $0.37 | $5.36 |
| Average True Range (ATR) | 0.03 | 0.28 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 12.62 | 82.66 |
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.